Core Viewpoint - The stock of the company,药捷安康-B (02617), has seen a significant increase, reaching a new high of 64.8 HKD, nearly quadrupling from its IPO price of 13.15 HKD, indicating strong market performance and investor interest [1] Group 1: Stock Performance - The stock price increased by over 8% during trading, peaking at 64.8 HKD, and is currently up 5.26% at 63 HKD with a trading volume of 11.809 million HKD [1] - The stock has appreciated nearly four times since its initial public offering [1] Group 2: Clinical Research - The company announced the completion of the first patient dosing in a Phase II clinical study for its core product,替恩戈替尼, in combination with 康方生物's 开坦尼 and 依达方 for the treatment of advanced hepatocellular carcinoma [1] - The study aims to evaluate the safety and efficacy of the combination therapy, targeting patients who have not previously received systemic anti-tumor therapy or have failed standard treatment for advanced hepatocellular carcinoma [1] Group 3: Index Inclusion - On August 22, the Hang Seng Index Company announced that the company will be included in the Hang Seng Composite Index, with changes effective after market close on September 5 and active from September 8 [1] - According to Huatai Securities, the company may be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing duration [1]
药捷安康-B涨超8%创新高 替恩戈替尼联用开坦尼/依达方的II期临床试验完成首例患者给药